Participants 14 94 3
bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS)
Participants 282 331 6
patients with progressive multiple sclerosis (MS)
Participants 870 912 5
employed at a single centre (Bristol, UK).
Participants 913 1085 7
Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS).
Participants 2306 2317 3
MS patients
